UF Tech Connect Program continuing to reap investments, add jobs

Posted by on Jul 22, 2014 in Newsroom | 0 comments

GAINESVILLE, FL - The University of Florida’s Tech Connect Program has racked up an impressive list of accomplishments in its first 12 years. The program helped spin off 157 companies using technology created by UF researchers, the UF Office of Technology Licensing reported Monday. Those companies have drawn more than $1 billion in private investments and $530 million in public grants, and helped create 2,000 new jobs, the OTL reported. In the past 12 months alone, companies associated with Tech Connect helped create 345 new jobs and raised more than $200 million in private and public...

Read More

Agile Sciences lands $1.5M NIH grant for cystic fribosis therapy

Posted by on Jul 17, 2014 in Newsroom | 0 comments

RESEARCH TRIANGLE PARK, N.C. – Biotechnology company Agile Sciences has landed a $1.5 million National Institutes of Health grant to help develop its cystic fibrosis therapy derived from sea sponges. Agile was spun out of North Carolina State University with the help of a $30,000 startup loan from the North Carolina Biotechnology Center. The company’s technology platform capitalizes on a chemical produced by the sea sponge to break up bacterial clumps called biofilms. The latest NIH grant supports pre-clinical development of Agile’s proprietary Agilyte anti-biofilm molecules for...

Read More

IRadimed Corporation Announces Pricing of Initial Public Offering

Posted by on Jul 17, 2014 in Newsroom | 0 comments

WINTER SPRINGS, FL. - IRADIMED CORPORATION (NASDAQ:IRMD), the leading provider of non-magnetic intravenous (IV) infusion pump systems that are safe for use during magnetic resonance imaging (MRI) procedures, announced today the pricing of its initial public offering of 2,016,000 shares of its common stock at an initial public offering price of $6.25 per share for a total offering amount of $12.6 million before deducting underwriting discounts and commissions, and estimated offering expenses payable by Iradimed. In addition, the underwriters have been granted a 45-day option to purchase up to...

Read More

Life science startups can get funding insight through NC Biotech Center library

Posted by on Jul 16, 2014 in Newsroom | 0 comments

RESEARCH TRIANGLE PARK, N.C. - North Carolina’s life science community now has a new way to glean inside information that might help with funding and business strategy. It comes via the North Carolina Biotechnology Center library’s subscription to the PitchBook private equity and venture capital database. By scheduling an appointment for an in-person visit to the library, users can scour PitchBook information on more than 42,000 investors and over 200,000 deals. The library is on the second floor of NCBiotech’s headquarters in Research Triangle Park. First-time users get the first...

Read More

Cortec opens state-of-the-art biotechnology campus in Florida

Posted by on Jul 15, 2014 in Newsroom | 0 comments

SARASOTA, FL. - Cortec® Corporation has announced the addition of its Cortec Biotechnology Campus, a state-of-the-art research facility featuring cutting-edge equipment for the manufacturing of the company’s Migratory Corrosion Inhibitor (MCI®), Vapor phase Corrosion Inhibitor (Nano-VpCI®) coatings and Bionetix’s bioremediation and cleaning products. The new Campus, located in Sarasota, Fla., comprises 36,000 square feet (3,600 square meters) of office, manufacturing, warehouse, and two laboratory areas under one roof. Part of the warehouse will be designated for...

Read More

NIH Awards Scripps Researchers $2.6M to Develop Stem Cell Lines

Posted by on Jul 15, 2014 in Newsroom | 0 comments

JUPITER, FL. - Scientists from the Florida campus of The Scripps Research Institute (TSRI) have been awarded a $2.6 million grant from the office of the director of the National Institutes of Health to produce specialized stems cells. Donald Phinney, a TSRI professor, will be the principal investigator for the new four-year project. His work involves mesenchymal stem cells, which are currently being evaluated in more than 180 open clinical trials. The mesenchymal stem cells produced by Phinney and his colleagues offer research results that are closer to what is expected from clinical trials....

Read More